![Andrew Westwell PhD PGCE HE](https://profiles-cardiff.imgix.net/attachments/2970?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Yr Athro Andrew Westwell
(e/fe)
PhD PGCE HE
- Sylwebydd y cyfryngau
Timau a rolau for Andrew Westwell
Athro Cemeg Meddyginiaethol a Phennaeth Ysgol
Trosolwyg
Ymunais â'r Ysgol Fferylliaeth a Gwyddorau Fferyllol ym mis Ionawr 2006. Fy niddordebau ymchwil:
- Dylunio a darganfod cyffuriau gwrth-ganser (cyn-glinigol).
- Dadansoddiad cemegol o sylweddau seicoweithredol newydd.
Yn benodol, mae fy ymchwil yn canolbwyntio ar ddarganfod a datblygu cyn-glinigol ymgeiswyr cyffuriau gwrth-ganser newydd sy'n targedu clefyd datblygedig a metastatig, achos marwolaeth mewn >90% o gleifion canser.
Cymwysterau
- PhD mewn cemeg organig synthetig, Prifysgol Leeds (1990-1993)
- BSc (Anrh) Cemeg, Prifysgol Leeds (1987-1990)
Newyddion
- Gwobrau Arloesi a Gofal Iechyd - 1 Mehefin 2016
- Cyfansoddyn bôn-gelloedd gwrth-ganser newydd yn cael ei ddatblygu - 7 Mai 2015
Cyhoeddiad
2026
- Kandil, S. B. et al. 2026. Coumarin-stavudine (d4T) novel hybrid ProTides with dual-functionality and enhanced anti-HIV activity. European Journal of Medicinal Chemistry 304 118543. (10.1016/j.ejmech.2025.118543)
2025
- Bordoni, C. et al. 2025. New anticancer 4‐aryldihydropyrimidinone‐5‐carboxylates targeting Hsp90. Chemical Biology & Drug Design 106 (6) e70221. (10.1111/cbdd.70221)
- Almehdi, A. M. et al., 2025. Next-generation Bcl-2 inhibitors: design and evaluation of indolyl-triazole derivatives with anticancer potential. ChemMedChem 20 e202500265. (10.1002/cmdc.202500265)
- Giancotti, G. et al. 2025. The discovery of small-molecule inhibitors of cFLIP that sensitise tumour cells to TNF-related apoptosis-inducing ligand. Academia Oncology 2 (2)(10.20935/AcadOnco7680)
2024
- Scott, A. T. and Westwell, A. D. 2024. Strategies to enhance the racial and ethnic diversity of breast cancer clinical drug trials. Academia Oncology 1 2. (10.20935/acadonco7480)
- Seaton, G. et al. 2024. Multifaceted roles for BCL3 in cancer: a proto-oncogene comes of age. Molecular Cancer 23 (1) 7. (10.1186/s12943-023-01922-8)
2023
- Almehdi, A. M. et al., 2023. Design, synthesis, and potent anticancer activity of novel indole-based Bcl-2 inhibitors. International Journal of Molecular Sciences 24 (19) 14656. (10.3390/ijms241914656)
2022
- Scurr, M. et al. 2022. Whole blood-based measurement of SARS-CoV-2-specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solid organ cancers. Immunology 165 (2), pp.250-259. (10.1111/imm.13433)
- Edwards, D. et al. 2022. A rapid scoping review of harm reduction strategies for ecstasy (MDMA) users in recreational settings. Research square (10.21203/rs.3.rs-2178425/v1)
2021
- Hamdy, R. et al., 2021. New bioactive fused triazolothiadiazoles as Bcl-2-targeted anticancer agents. International Journal of Molecular Sciences 22 (22) 12272. (10.3390/ijms222212272)
- Soukupova, J. et al., 2021. The discovery of a novel anti-metastatic Bcl3 inhibitor. Molecular Cancer Therapeutics 10 (5), pp.775-786. (10.1158/1535-7163.MCT-20-0283)
- Kandil, S. B. et al. 2021. Synthesis, biological evaluation and X-ray analysis of bicalutamide sulfoxide analogues for the potential treatment of prostate cancer. Bioorganic and Medicinal Chemistry Letters 36 127817. (10.1016/j.bmcl.2021.127817)
- Kourti, M. et al. 2021. Structural modifications on CORM-3 lead to enhanced anti-angiogenic properties against triple-negative breast cancer cells. Medicinal Chemistry 17 (1), pp.40-59. (10.2174/1573406415666191206102452)
- James, E. et al. 2021. Online survey into the development of a model legal framework for a cannabis market in the United Kingdom. Drug Science, Policy and Law 7 (10.1177/20503245211034931)
- Kandil, S. B. , McGuigan, C. and Westwell, A. D. 2021. Synthesis and biological evaluation of bicalutamide analogues for the potential treatment of prostate cancer. Molecules 26 (1) 56. (10.3390/molecules26010056)
2020
- Hamdy, R. et al., 2020. Design, synthesis and evaluation of new bioactive oxadiazole derivatives as anticancer agents targeting Bcl-2. International Journal of Molecular Sciences 21 (23) 8980. (10.3390/ijms21238980)
- Kandil, S. B. et al. 2020. Structure-based virtual screening, synthesis and biological evaluation of potential FAK-FAT domain inhibitors for treatment of metastatic cancer. Molecules 25 (15) 3488. (10.3390/molecules25153488)
- Cavaliere, A. et al. 2020. Radiosynthesis of [18F]-labelled pro-nucleotides (ProTides). Molecules 25 (3) 704. (10.3390/molecules25030704)
2019
- Kandil, S. et al. 2019. Polyfluoroaromatic stavudine (d4T) ProTides exhibit enhanced anti-HIV activity. Bioorganic and Medicinal Chemistry Letters 29 (24) 126721. (10.1016/j.bmcl.2019.126721)
- Pertusati, F. et al. 2019. A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF5) and pentafluoroethyl (C2F5) substituents: Improved antiproliferative agents against prostate cancer. European Journal of Medicinal Chemistry 180 , pp.1-14. (10.1016/j.ejmech.2019.07.001)
- Crusco, A. et al. 2019. Antischistosomal properties of sclareol and its heck-coupled derivatives: Design, synthesis, biological evaluation, and untargeted metabolomics. ACS Infectious Diseases 5 (7), pp.1188-1199. (10.1021/acsinfecdis.9b00034)
- Crusco, A. et al. 2019. The anti-mycobacterial activity of a diterpenoid-like molecule operates through nitrogen and amino acid starvation. Frontiers in Microbiology 10 1444. (10.3389/fmicb.2019.01444)
- Hamdy, R. et al., 2019. New quinoline-based heterocycles as anticancer agents targeting Bcl-2. Molecules 24 (7), pp.1274. (10.3390/molecules24071274)
- Kandil, S. et al. 2019. Discovery of deshydroxy bicalutamide derivatives as androgen receptor antagonists. European Journal of Medicinal Chemistry 167 , pp.49-60. (10.1016/j.ejmech.2019.01.054)
- Anderson, R. L. et al., 2019. A framework for the development of effective anti-metastatic agents. Nature Reviews Clinical Oncology 16 , pp.185-204. (10.1038/s41571-018-0134-8)
- James, E. , Robertshaw, T. L. and Westwell, A. D. 2019. Emerging from the dark side: new therapeutic applications of scheduled psychoactive substances. Future Medicinal Chemistry 11 (3)(10.4155/fmc-2018-0447)
- Fosu-Mensah, N. A. et al. 2019. The discovery of purine-based agents targeting triple-negative breast cancer and the αB-crystallin/VEGF protein-protein interaction. Medicinal Chemistry Research 28 (2), pp.182-202. (10.1007/s00044-018-2275-9)
- Kourti, M. et al. 2019. Repurposing old carbon monoxide-releasing molecules towards the anti-angiogenic therapy of triple-negative breast cancer. Oncotarget 10 (10), pp.1132-1148. (10.18632/oncotarget.26638)
- James, E. et al. 2019. Using the pharmacy retail model to examine perceptions and biases of a UK population sample towards regulation of specific psychoactive drugs.. Drug Science, Policy and Law 5 (10.1177/2050324519876123)
2018
- Shirinzadeh, H. et al., 2018. Antimicrobial activities of new indole derivatives containing 1,2,4-Triazole, 1,3,4-Thiadiazole and Carbothioamide. The Turkish Journal of Pharmaceutical Sciences 15 (3), pp.291-297. (10.4274/tjps.55707)
- Dart, D. A. et al. 2018. Novel trifluoromethylated enobosarm analogues with potent antiandrogenic activity in vitro and tissue selectivity in vivo. Molecular Cancer Therapeutics 17 (9), pp.1846-1858. (10.1158/1535-7163.MCT-18-0037)
- Crusco, A. et al. 2018. Design, synthesis and anthelmintic activity of 7-keto-sempervirol analogues. European Journal of Medicinal Chemistry 152 , pp.87-100. (10.1016/j.ejmech.2018.04.032)
- James, E. et al. 2018. Pharmacies as potential providers of harm reduction services: A preliminary online survey. Drug Science, Policy and Law 4 , pp.1-14. (10.1177/2050324518767441)
- Kandil, S. et al. 2018. The discovery of new and more potent chloropyramine (C4) analogues for the potential treatment of invasive breast cancer. Chemical Biology and Drug Design 91 (1), pp.314-321. (10.1111/cbdd.13083)
2017
- Somasagara, R. R. et al., 2017. RAD6 promotes DNA repair and stem cell signaling in ovarian cancer and is a promising therapeutic target to prevent and treat acquired chemoresistance. Oncogene 36 , pp.6680-6690. (10.1038/onc.2017.279)
- Cavaliere, A. et al. 2017. Fluorinated nucleosides as an important class of anticancer and antiviral agents. Future Medicinal Chemistry 9 (15)
- Hendriks, H. R. et al., 2017. Pharmacologically directed strategies in academic anticancer drug discovery based on the European NCI compounds initiative. British Journal of Cancer 117 , pp.195-202. (10.1038/bjc.2017.167)
- Bassetto, M. et al. 2017. Rational design and synthesis of novel phenylsulfonyl-benzamides as anti-prostate cancer agents. MedChemComm 8 (7), pp.1414-1420. (10.1039/C7MD00164A)
- Hamdy, R. et al., 2017. Synthesis and evaluation of 5-(1H-indol-3-yl)-N-aryl-1,3,4-oxadiazol-2-amines as Bcl-2 inhibitory anticancer agents. Bioorganic & Medicinal Chemistry Letters 27 (4), pp.1037-1040. (10.1016/j.bmcl.2016.12.061)
- Ziedan, N. I. et al., 2017. Virtual screening, SAR and discovery of 5-(indole-3-yl)-2-[(2-nitrophenyl)amino] [1,3,4]-oxadiazole as a novel Bcl-2 inhibitor. Chemical Biology and Drug Design (10.1111/cbdd.12936)
2016
- Wymant, J. et al. 2016. The Role of BCA2 in the endocytic trafficking of EGFR and significance as a prognostic biomarker in cancer. Journal of Cancer 7 (15), pp.2388-2407. (10.7150/jca.15055)
- Kandil, S. et al. 2016. ProTides of BVdU as potential anticancer agents upon efficient intracellular delivery of their activated metabolites. Biorganic and Medicinal Chemistry Letters 26 (23), pp.5618-5623. (10.1016/j.bmcl.2016.10.077)
- Bassetto, M. et al. 2016. Design and synthesis of novel bicalutamide and enzalutamide derivatives as antiproliferative agents for the treatment of prostate cancer. European Journal of Medicinal Chemistry 118 , pp.230-243. (10.1016/j.ejmech.2016.04.052)
- Ferla, S. et al. 2016. Rational design and synthesis of novel anti-prostate cancer agents bearing a 3,5-bis-trifluoromethylphenyl moiety. Bioorganic and Medicinal Chemistry Letters 26 (15), pp.3636-3640. (10.1016/j.bmcl.2016.06.001)
- Haynes, B. et al., 2016. Gold nanoparticle conjugated Rad6 inhibitor induces cell death in triple negative breast cancer cells by inducing mitochondrial dysfunction and PARP-1 hyperactivation: Synthesis and characterization. Nanomedicine: Nanotechnology, Biology and Medicine 12 (3), pp.745-757. (10.1016/j.nano.2015.10.010)
- Kothayer, H. et al., 2016. Synthesis and in vitro anticancer evaluation of some 4,6-diamino-1,3,5-triazine-2-carbohydrazides as Rad6 ubiquitin conjugating enzyme inhibitors. Biorganic and Medicinal Chemistry Letters 26 (8), pp.2030-2034. (10.1016/j.bmcl.2016.02.085)
- Kandil, S. et al. 2016. Novel cis-selective and non-epimerisable C3 hydroxy azapodophyllotoxins targeting microtubules in cancer cells. European Journal of Medicinal Chemistry 110 , pp.311-325. (10.1016/j.ejmech.2015.12.037)
- Westwell, A. D. ed. 2016. Fluorinated pharmaceuticals: advances in medicinal chemistry. Future Medicine. (10.4155/9781909453968)
- Kandil, S. , Westwell, A. D. and McGuigan, C. 2016. 7-Substituted umbelliferone derivatives as androgen receptor antagonists for the potential treatment of prostate and breast cancer. Biorganic and Medicinal Chemistry Letters 26 (8), pp.2000-2004. (10.1016/j.bmcl.2016.02.088)
- Shirinzadeh, H. et al., 2016. Novel indole-based melatonin analogues substituted with triazole, thiadiazole and carbothioamides: studies on their antioxidant, chemopreventive and cytotoxic activities. Journal of Enzyme Inhibition and Medicinal Chemistry 31 (6), pp.1312-1321. (10.3109/14756366.2015.1132209)
2015
- Edwards, R. et al. 2015. Solid-supported iodonium salts for fluorinations. European Journal of Organic Chemistry 2015 (31), pp.6909-6916. (10.1002/ejoc.201500992)
- Cilibrasi, V. et al. 2015. Synthesis of substituted carbamo(dithioperoxo)thioates as potential BCA2-inhibitory anticancer agents. Tetrahedron Letters 56 (20), pp.2583-2585. (10.1016/j.tetlet.2015.03.132)
- Wiggins, H. L. et al. 2015. Disulfiram-induced cytotoxicity and endo-lysosomal sequestration of zinc in breast cancer cells. Biochemical Pharmacology 93 (3), pp.332-342. (10.1016/j.bcp.2014.12.014)
- Edwards, R. et al. 2015. Convenient synthesis of diaryliodonium salts for the production of [18F]F-DOPA. European Journal of Organic Chemistry 2015 (3), pp.625-630. (10.1002/ejoc.201403378)
- Fosu-Mensah, N. et al. 2015. Advances in small-molecule drug discovery for triple-negative breast cancer. Future Medicinal Chemistry 7 (15), pp.2019-2039. (10.4155/fmc.15.129)
2014
- Meyer, J. , Probst, K. C. and Westwell, A. D. 2014. Radiochemical synthesis of 2′-[18F]-labelled and 3′-[18F]-labelled nucleosides for positron emission tomography imaging. Journal of Labelled Compounds and Radiopharmaceuticals 57 (5), pp.333-337. (10.1002/jlcr.3197)
- Velanguparackel, W. et al. 2014. Synthesis, anti-HIV and cytostatic evaluation of 3′-deoxy-3′-fluorothymidine (FLT) pro-nucleotides. Bioorganic and Medicinal Chemistry Letters 24 (10), pp.2240-2243. (10.1016/j.bmcl.2014.03.092)
- Meyer, J. et al. 2014. A novel radiochemical approach to 1-(2 '-deoxy-2 '-[F-18] fluoro-beta-D-arabinofuranosyl)cytosine (F-18-FAC). Journal of Labelled Compounds and Radiopharmaceuticals 57 (11), pp.637-644. (10.1002/jlcr.3233)
2013
- Hamdy, R. et al., 2013. Synthesis and evaluation of 3-(benzylthio)-5-(1H-indol-3-yl)-1,2,4-triazol-4-amines as Bcl-2 inhibitory anticancer agents. Biorganic and Medicinal Chemistry Letters 23 (8), pp.2391-2394. (10.1016/j.bmcl.2013.02.029)
- Karaaslan, C. et al. 2013. Synthesis and antioxidant properties of substituted 2-phenyl-1H-indoles. Biorganic and Medicinal Chemistry Letters 23 (9), pp.2671-2674. (10.1016/j.bmcl.2013.02.090)
- Kothayer, H. et al., 2013. Design, synthesis and in vitro anticancer evaluation of 4,6-diamino-1,3,5-triazine-2-carbohydrazides and -carboxamides. Biorganic and Medicinal Chemistry Letters 23 (24), pp.6886-6889. (10.1016/j.bmcl.2013.09.087)
- Sanders, M. A. et al., 2013. Novel inhibitors of Rad6 ubiquitin conjugating enzyme: Design, synthesis, identification, and functional characterization. Molecular Cancer Therapeutics 12 (4), pp.373-383. (10.1158/1535-7163.MCT-12-0793)
- Tekiner-Gulbas, B. , Westwell, A. D. and Suzen, S. 2013. Oxidative stress in carcinogenesis: new synthetic compounds with dual effects upon free radicals and cancer. Current Medicinal Chemistry 20 (36), pp.4451-4459. (10.2174/09298673113203690142)
- Weekes, A. A. , Frydrych, J. and Westwell, A. D. 2013. Convenient synthesis of substituted 2-phenylbenzothiazoles using solid-supported triphenylphosphine. Synthetic Communications 43 (19), pp.2656-2662. (10.1080/00397911.2012.730648)
- Westwell, A. D. , Hutchings, A. and Caldicott, D. G. E. 2013. The identification and chemical characterization of a new arylcyclohexylamine, methoxetamine, using a novel Emergency Department toxicosurveillance tool. Drug Testing and Analysis 5 (3), pp.203-207. (10.1002/dta.1375)
2012
- Md Tohid, S. F. et al. 2012. Synthesis and evaluation of indole-containing 3,5-diarylisoxazoles as potential pro-apoptotic antitumour agents. European Journal of Medicinal Chemistry 56 , pp.263-270. (10.1016/j.ejmech.2012.08.009)
- Soukupova, J. et al., 2012. Inhibitors of Bcl-3 as a novel therapeutic strategy for HER2+ breast cancer. European Journal of Cancer 48 (5), pp.S225-S225.
2011
- Cottens, S. et al., 2011. Ask the experts: future of the pharmaceutical industry. Future Medicinal Chemistry 3 (15)(10.4155/fmc.11.145)
- Altug, C. et al., 2011. An efficient one-pot multicomponent approach to 5-amino-7-aryl-8-nitrothiazolo[3,2-a]pyridines. Tetrahedron 67 (49), pp.9522-9528. (10.1016/j.tet.2011.10.005)
- Weekes, A. A. , Bagley, M. C. and Westwell, A. D. 2011. An efficient synthetic route to biologically relevant 2-phenylbenzothiazoles substituted on the benzothiazole ring. Tetrahedron 67 (40), pp.7743-7747. (10.1016/j.tet.2011.08.004)
2010
- Brahemi, G. et al. 2010. Exploring the structural requirements for inhibition of the ubiquitin E3 ligase breast cancer associated protein 2 (BCA2) as a treatment for breast cancer. Journal of Medicinal Chemistry 53 (7), pp.2757-2765. (10.1021/jm901757t)
- Chew, E. et al., 2010. Cinnamaldehydes inhibit thioredoxin reductase and induce Nrf2: potential candidates for cancer therapy and chemoprevention. Free Radical Biology & Medicine 48 (1), pp.98-111. (10.1016/j.freeradbiomed.2009.10.028)
- Brahemi, G. et al. 2010. Homology Modelling of Human E1 Ubiquitin Activating Enzyme. Letters in Drug Design & Discovery 7 (1), pp.57-62. (10.2174/157018010789869316)
- Bruyere, H. , Westwell, A. and Jones, A. T. 2010. Tuning the pH sensitivities of orthoester based compounds for drug delivery applications by simple chemical modification. Bioorganic & Medicinal Chemistry Letters 20 (7), pp.2200-2203. (10.1016/j.bmcl.2010.02.035)
- Daniels, S. et al. 2010. The role and future potential of fluorinated biomarkers in positron emission tomography. Expert Opinion on Drug Discovery 5 (3), pp.291-304. (10.1517/17460441003652967)
- Weekes, A. A. et al., 2010. Rapid and convenient thermal or microwave-assisted synthesis of substituted 2-Phenylbenzothiazoles. Synthetic Communications 40 (20), pp.3027-3032. (10.1080/00397910903353739)
- Ziedan, N. I. et al., 2010. Design, synthesis and pro-apoptotic antitumour properties of indole-based 3,5-disubstituted oxadiazoles. European Journal of Medicinal Chemistry 45 (10), pp.4523-4530. (10.1016/j.ejmech.2010.07.012)
2009
- Gan, F. F. et al., 2009. Structure-activity analysis of 2 '-modified cinnamaldehyde analogues as potential anticancer agents. Biochemical and Biophysical Research Communications 387 (4), pp.741-747. (10.1016/j.bbrc.2009.07.104)
- Weekes, A. A. and Westwell, A. 2009. 2-Arylbenzothiazole as a Privileged Scaffold in Drug Discovery. Current Medicinal Chemistry 16 (19), pp.2430-2440.
2008
- Aiello, S. et al. 2008. Synthesis and biological properties of benzothiazole, benzoxazole, and chromen-4-one analogues of the potent antitumor agent 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (PMX 610, NSC 721648). Journal of Medicinal Chemistry 51 (16), pp.5135-5139. (10.1021/jm800418z)
- Brahemi, G. et al. 2008. Design and synthesis of BCA2 inhibitors. EJC Supplements 6 (12), pp.44.
- Huber, K. et al., 2008. 2- [(1-methylpropyl)dithio] -1H-imidazole inhibits tubulin polymerization through cysteine oxidation. Molecular Cancer Therapeutics 7 (1), pp.143-151. (10.1158/1535-7163.mct-07-0486)
- Kadri, H. et al. 2008. The design, synthesis and antitumour evaluation of novel small molecule inhibitors of the Dishevelled PDZ domain [Poster Presentation/Abstract]. EJC Supplements 6 (12), pp.137. 436. (10.1016/S1359-6349(08)72370-X)
- Kadri, H. et al. 2008. Synthesis and antitumour evaluation of novel 2-phenylbenzimidazoles. Journal of Enzyme Inhibition and Medicinal Chemistry 23 (5), pp.641-647. (10.1080/14756360802205398)
- Westwell, A. 2008. Advances in Cancer Drug Discovery - A British Association for Cancer Research Meeting. IDrugs 11 (11), pp.783-786.
- White, A. W. , Westwell, A. and Brahemi, G. 2008. Protein-protein interactions as targets for small-molecule therapeutics in cancer. Expert Reviews in Molecular Medicine 10 (e8), pp.1-14. (10.1017/S1462399408000641)
- Ziedan, N. , Westwell, A. and Fogli, S. 2008. Design and synthesis of novel indole derivatives as selective apoptosis-inducers. EJC Supplements 6 (12), pp.45-46.
2007
- Athanasiou, A. et al., 2007. Cannabinoid receptor agonists are mitochondrial inhibitors: A unified hypothesis of how cannabinoids modulate mitochondrial function and induce cell death. Biochemical and Biophysical Research Communications 364 (1), pp.131-137. (10.1016/j.bbrc.2007.09.107)
- Athanasiou, A. et al., 2007. Vanilloid receptor agonists and antagonists are mitochondrial inhibitors: how vanilloids cause non-vanilloid receptor mediated cell death. Biochemical and Biophysical Research Communications 354 (1), pp.50-55. (10.1016/j.bbrc.2006.12.179)
- Henriksen, G. et al., 2007. Metabolically stabilized benzothiazoles for imaging of amyloid plaques. Journal of Medicinal Chemistry 50 (6), pp.1087-1089. (10.1021/jm061466g)
- Matsuura, T. et al., 2007. Basal and angiotensin II-inhibited neuronal delayed-rectifier K+ current are regulated by thioredoxin. American Journal of Physiology -Cell Physiology 293 (1), pp.C211-C217. (10.1152/ajpcell.00615.2006)
2006
- Westwell, A. D. et al. 2006. Antitumor benzothiazoles. 26. 2-(3,4-Dimethoxyphenyl)-5-fluorobenzothiazole (GW 610, NSC 721648), a simple fluorinated 2-arylbenzothiazole, shows potent and selective inhibitory activity against lung, colon, and breast cancer cell lines. Journal of Medicinal Chemistry 49 (1), pp.179-185. (10.1021/jm050942k)
2005
- Westwell, A. D. et al. 2005. Quinols as novel therapeutic agents. 2. 4-(1-Arylsulfonylindol-2-yl)-4-hydroxycyclohexa-2,5-dien-1-ones and related agents as potent and selective antitumor agents. Journal of Medicinal Chemistry 48 (2), pp.639-644. (10.1021/jm040859h)
2003
- Westwell, A. D. et al. 2003. 4-Substituted-4-hydroxycyclohexa-2,5-dien-1-ones with selective activities against colon and renal cancer cell lines. Journal of Medicinal Chemistry 46 (4), pp.532-541. (10.1021/jm020984y)
2001
- Hutchinson, I. et al., 2001. Antitumor benzothiazoles. 14. Synthesis and in vitro biological properties of fluorinated 2-(4-aminophenyl)benzothiazoles. Journal of Medicinal Chemistry 44 (9), pp.1446-1455. (10.1021/jm001104n)
Erthyglau
- Kandil, S. B. et al. 2026. Coumarin-stavudine (d4T) novel hybrid ProTides with dual-functionality and enhanced anti-HIV activity. European Journal of Medicinal Chemistry 304 118543. (10.1016/j.ejmech.2025.118543)
- Bordoni, C. et al. 2025. New anticancer 4‐aryldihydropyrimidinone‐5‐carboxylates targeting Hsp90. Chemical Biology & Drug Design 106 (6) e70221. (10.1111/cbdd.70221)
- Almehdi, A. M. et al., 2025. Next-generation Bcl-2 inhibitors: design and evaluation of indolyl-triazole derivatives with anticancer potential. ChemMedChem 20 e202500265. (10.1002/cmdc.202500265)
- Giancotti, G. et al. 2025. The discovery of small-molecule inhibitors of cFLIP that sensitise tumour cells to TNF-related apoptosis-inducing ligand. Academia Oncology 2 (2)(10.20935/AcadOnco7680)
- Scott, A. T. and Westwell, A. D. 2024. Strategies to enhance the racial and ethnic diversity of breast cancer clinical drug trials. Academia Oncology 1 2. (10.20935/acadonco7480)
- Seaton, G. et al. 2024. Multifaceted roles for BCL3 in cancer: a proto-oncogene comes of age. Molecular Cancer 23 (1) 7. (10.1186/s12943-023-01922-8)
- Almehdi, A. M. et al., 2023. Design, synthesis, and potent anticancer activity of novel indole-based Bcl-2 inhibitors. International Journal of Molecular Sciences 24 (19) 14656. (10.3390/ijms241914656)
- Scurr, M. et al. 2022. Whole blood-based measurement of SARS-CoV-2-specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solid organ cancers. Immunology 165 (2), pp.250-259. (10.1111/imm.13433)
- Edwards, D. et al. 2022. A rapid scoping review of harm reduction strategies for ecstasy (MDMA) users in recreational settings. Research square (10.21203/rs.3.rs-2178425/v1)
- Hamdy, R. et al., 2021. New bioactive fused triazolothiadiazoles as Bcl-2-targeted anticancer agents. International Journal of Molecular Sciences 22 (22) 12272. (10.3390/ijms222212272)
- Soukupova, J. et al., 2021. The discovery of a novel anti-metastatic Bcl3 inhibitor. Molecular Cancer Therapeutics 10 (5), pp.775-786. (10.1158/1535-7163.MCT-20-0283)
- Kandil, S. B. et al. 2021. Synthesis, biological evaluation and X-ray analysis of bicalutamide sulfoxide analogues for the potential treatment of prostate cancer. Bioorganic and Medicinal Chemistry Letters 36 127817. (10.1016/j.bmcl.2021.127817)
- Kourti, M. et al. 2021. Structural modifications on CORM-3 lead to enhanced anti-angiogenic properties against triple-negative breast cancer cells. Medicinal Chemistry 17 (1), pp.40-59. (10.2174/1573406415666191206102452)
- James, E. et al. 2021. Online survey into the development of a model legal framework for a cannabis market in the United Kingdom. Drug Science, Policy and Law 7 (10.1177/20503245211034931)
- Kandil, S. B. , McGuigan, C. and Westwell, A. D. 2021. Synthesis and biological evaluation of bicalutamide analogues for the potential treatment of prostate cancer. Molecules 26 (1) 56. (10.3390/molecules26010056)
- Hamdy, R. et al., 2020. Design, synthesis and evaluation of new bioactive oxadiazole derivatives as anticancer agents targeting Bcl-2. International Journal of Molecular Sciences 21 (23) 8980. (10.3390/ijms21238980)
- Kandil, S. B. et al. 2020. Structure-based virtual screening, synthesis and biological evaluation of potential FAK-FAT domain inhibitors for treatment of metastatic cancer. Molecules 25 (15) 3488. (10.3390/molecules25153488)
- Cavaliere, A. et al. 2020. Radiosynthesis of [18F]-labelled pro-nucleotides (ProTides). Molecules 25 (3) 704. (10.3390/molecules25030704)
- Kandil, S. et al. 2019. Polyfluoroaromatic stavudine (d4T) ProTides exhibit enhanced anti-HIV activity. Bioorganic and Medicinal Chemistry Letters 29 (24) 126721. (10.1016/j.bmcl.2019.126721)
- Pertusati, F. et al. 2019. A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF5) and pentafluoroethyl (C2F5) substituents: Improved antiproliferative agents against prostate cancer. European Journal of Medicinal Chemistry 180 , pp.1-14. (10.1016/j.ejmech.2019.07.001)
- Crusco, A. et al. 2019. Antischistosomal properties of sclareol and its heck-coupled derivatives: Design, synthesis, biological evaluation, and untargeted metabolomics. ACS Infectious Diseases 5 (7), pp.1188-1199. (10.1021/acsinfecdis.9b00034)
- Crusco, A. et al. 2019. The anti-mycobacterial activity of a diterpenoid-like molecule operates through nitrogen and amino acid starvation. Frontiers in Microbiology 10 1444. (10.3389/fmicb.2019.01444)
- Hamdy, R. et al., 2019. New quinoline-based heterocycles as anticancer agents targeting Bcl-2. Molecules 24 (7), pp.1274. (10.3390/molecules24071274)
- Kandil, S. et al. 2019. Discovery of deshydroxy bicalutamide derivatives as androgen receptor antagonists. European Journal of Medicinal Chemistry 167 , pp.49-60. (10.1016/j.ejmech.2019.01.054)
- Anderson, R. L. et al., 2019. A framework for the development of effective anti-metastatic agents. Nature Reviews Clinical Oncology 16 , pp.185-204. (10.1038/s41571-018-0134-8)
- James, E. , Robertshaw, T. L. and Westwell, A. D. 2019. Emerging from the dark side: new therapeutic applications of scheduled psychoactive substances. Future Medicinal Chemistry 11 (3)(10.4155/fmc-2018-0447)
- Fosu-Mensah, N. A. et al. 2019. The discovery of purine-based agents targeting triple-negative breast cancer and the αB-crystallin/VEGF protein-protein interaction. Medicinal Chemistry Research 28 (2), pp.182-202. (10.1007/s00044-018-2275-9)
- Kourti, M. et al. 2019. Repurposing old carbon monoxide-releasing molecules towards the anti-angiogenic therapy of triple-negative breast cancer. Oncotarget 10 (10), pp.1132-1148. (10.18632/oncotarget.26638)
- James, E. et al. 2019. Using the pharmacy retail model to examine perceptions and biases of a UK population sample towards regulation of specific psychoactive drugs.. Drug Science, Policy and Law 5 (10.1177/2050324519876123)
- Shirinzadeh, H. et al., 2018. Antimicrobial activities of new indole derivatives containing 1,2,4-Triazole, 1,3,4-Thiadiazole and Carbothioamide. The Turkish Journal of Pharmaceutical Sciences 15 (3), pp.291-297. (10.4274/tjps.55707)
- Dart, D. A. et al. 2018. Novel trifluoromethylated enobosarm analogues with potent antiandrogenic activity in vitro and tissue selectivity in vivo. Molecular Cancer Therapeutics 17 (9), pp.1846-1858. (10.1158/1535-7163.MCT-18-0037)
- Crusco, A. et al. 2018. Design, synthesis and anthelmintic activity of 7-keto-sempervirol analogues. European Journal of Medicinal Chemistry 152 , pp.87-100. (10.1016/j.ejmech.2018.04.032)
- James, E. et al. 2018. Pharmacies as potential providers of harm reduction services: A preliminary online survey. Drug Science, Policy and Law 4 , pp.1-14. (10.1177/2050324518767441)
- Kandil, S. et al. 2018. The discovery of new and more potent chloropyramine (C4) analogues for the potential treatment of invasive breast cancer. Chemical Biology and Drug Design 91 (1), pp.314-321. (10.1111/cbdd.13083)
- Somasagara, R. R. et al., 2017. RAD6 promotes DNA repair and stem cell signaling in ovarian cancer and is a promising therapeutic target to prevent and treat acquired chemoresistance. Oncogene 36 , pp.6680-6690. (10.1038/onc.2017.279)
- Cavaliere, A. et al. 2017. Fluorinated nucleosides as an important class of anticancer and antiviral agents. Future Medicinal Chemistry 9 (15)
- Hendriks, H. R. et al., 2017. Pharmacologically directed strategies in academic anticancer drug discovery based on the European NCI compounds initiative. British Journal of Cancer 117 , pp.195-202. (10.1038/bjc.2017.167)
- Bassetto, M. et al. 2017. Rational design and synthesis of novel phenylsulfonyl-benzamides as anti-prostate cancer agents. MedChemComm 8 (7), pp.1414-1420. (10.1039/C7MD00164A)
- Hamdy, R. et al., 2017. Synthesis and evaluation of 5-(1H-indol-3-yl)-N-aryl-1,3,4-oxadiazol-2-amines as Bcl-2 inhibitory anticancer agents. Bioorganic & Medicinal Chemistry Letters 27 (4), pp.1037-1040. (10.1016/j.bmcl.2016.12.061)
- Ziedan, N. I. et al., 2017. Virtual screening, SAR and discovery of 5-(indole-3-yl)-2-[(2-nitrophenyl)amino] [1,3,4]-oxadiazole as a novel Bcl-2 inhibitor. Chemical Biology and Drug Design (10.1111/cbdd.12936)
- Wymant, J. et al. 2016. The Role of BCA2 in the endocytic trafficking of EGFR and significance as a prognostic biomarker in cancer. Journal of Cancer 7 (15), pp.2388-2407. (10.7150/jca.15055)
- Kandil, S. et al. 2016. ProTides of BVdU as potential anticancer agents upon efficient intracellular delivery of their activated metabolites. Biorganic and Medicinal Chemistry Letters 26 (23), pp.5618-5623. (10.1016/j.bmcl.2016.10.077)
- Bassetto, M. et al. 2016. Design and synthesis of novel bicalutamide and enzalutamide derivatives as antiproliferative agents for the treatment of prostate cancer. European Journal of Medicinal Chemistry 118 , pp.230-243. (10.1016/j.ejmech.2016.04.052)
- Ferla, S. et al. 2016. Rational design and synthesis of novel anti-prostate cancer agents bearing a 3,5-bis-trifluoromethylphenyl moiety. Bioorganic and Medicinal Chemistry Letters 26 (15), pp.3636-3640. (10.1016/j.bmcl.2016.06.001)
- Haynes, B. et al., 2016. Gold nanoparticle conjugated Rad6 inhibitor induces cell death in triple negative breast cancer cells by inducing mitochondrial dysfunction and PARP-1 hyperactivation: Synthesis and characterization. Nanomedicine: Nanotechnology, Biology and Medicine 12 (3), pp.745-757. (10.1016/j.nano.2015.10.010)
- Kothayer, H. et al., 2016. Synthesis and in vitro anticancer evaluation of some 4,6-diamino-1,3,5-triazine-2-carbohydrazides as Rad6 ubiquitin conjugating enzyme inhibitors. Biorganic and Medicinal Chemistry Letters 26 (8), pp.2030-2034. (10.1016/j.bmcl.2016.02.085)
- Kandil, S. et al. 2016. Novel cis-selective and non-epimerisable C3 hydroxy azapodophyllotoxins targeting microtubules in cancer cells. European Journal of Medicinal Chemistry 110 , pp.311-325. (10.1016/j.ejmech.2015.12.037)
- Kandil, S. , Westwell, A. D. and McGuigan, C. 2016. 7-Substituted umbelliferone derivatives as androgen receptor antagonists for the potential treatment of prostate and breast cancer. Biorganic and Medicinal Chemistry Letters 26 (8), pp.2000-2004. (10.1016/j.bmcl.2016.02.088)
- Shirinzadeh, H. et al., 2016. Novel indole-based melatonin analogues substituted with triazole, thiadiazole and carbothioamides: studies on their antioxidant, chemopreventive and cytotoxic activities. Journal of Enzyme Inhibition and Medicinal Chemistry 31 (6), pp.1312-1321. (10.3109/14756366.2015.1132209)
- Edwards, R. et al. 2015. Solid-supported iodonium salts for fluorinations. European Journal of Organic Chemistry 2015 (31), pp.6909-6916. (10.1002/ejoc.201500992)
- Cilibrasi, V. et al. 2015. Synthesis of substituted carbamo(dithioperoxo)thioates as potential BCA2-inhibitory anticancer agents. Tetrahedron Letters 56 (20), pp.2583-2585. (10.1016/j.tetlet.2015.03.132)
- Wiggins, H. L. et al. 2015. Disulfiram-induced cytotoxicity and endo-lysosomal sequestration of zinc in breast cancer cells. Biochemical Pharmacology 93 (3), pp.332-342. (10.1016/j.bcp.2014.12.014)
- Edwards, R. et al. 2015. Convenient synthesis of diaryliodonium salts for the production of [18F]F-DOPA. European Journal of Organic Chemistry 2015 (3), pp.625-630. (10.1002/ejoc.201403378)
- Fosu-Mensah, N. et al. 2015. Advances in small-molecule drug discovery for triple-negative breast cancer. Future Medicinal Chemistry 7 (15), pp.2019-2039. (10.4155/fmc.15.129)
- Meyer, J. , Probst, K. C. and Westwell, A. D. 2014. Radiochemical synthesis of 2′-[18F]-labelled and 3′-[18F]-labelled nucleosides for positron emission tomography imaging. Journal of Labelled Compounds and Radiopharmaceuticals 57 (5), pp.333-337. (10.1002/jlcr.3197)
- Velanguparackel, W. et al. 2014. Synthesis, anti-HIV and cytostatic evaluation of 3′-deoxy-3′-fluorothymidine (FLT) pro-nucleotides. Bioorganic and Medicinal Chemistry Letters 24 (10), pp.2240-2243. (10.1016/j.bmcl.2014.03.092)
- Meyer, J. et al. 2014. A novel radiochemical approach to 1-(2 '-deoxy-2 '-[F-18] fluoro-beta-D-arabinofuranosyl)cytosine (F-18-FAC). Journal of Labelled Compounds and Radiopharmaceuticals 57 (11), pp.637-644. (10.1002/jlcr.3233)
- Hamdy, R. et al., 2013. Synthesis and evaluation of 3-(benzylthio)-5-(1H-indol-3-yl)-1,2,4-triazol-4-amines as Bcl-2 inhibitory anticancer agents. Biorganic and Medicinal Chemistry Letters 23 (8), pp.2391-2394. (10.1016/j.bmcl.2013.02.029)
- Karaaslan, C. et al. 2013. Synthesis and antioxidant properties of substituted 2-phenyl-1H-indoles. Biorganic and Medicinal Chemistry Letters 23 (9), pp.2671-2674. (10.1016/j.bmcl.2013.02.090)
- Kothayer, H. et al., 2013. Design, synthesis and in vitro anticancer evaluation of 4,6-diamino-1,3,5-triazine-2-carbohydrazides and -carboxamides. Biorganic and Medicinal Chemistry Letters 23 (24), pp.6886-6889. (10.1016/j.bmcl.2013.09.087)
- Sanders, M. A. et al., 2013. Novel inhibitors of Rad6 ubiquitin conjugating enzyme: Design, synthesis, identification, and functional characterization. Molecular Cancer Therapeutics 12 (4), pp.373-383. (10.1158/1535-7163.MCT-12-0793)
- Tekiner-Gulbas, B. , Westwell, A. D. and Suzen, S. 2013. Oxidative stress in carcinogenesis: new synthetic compounds with dual effects upon free radicals and cancer. Current Medicinal Chemistry 20 (36), pp.4451-4459. (10.2174/09298673113203690142)
- Weekes, A. A. , Frydrych, J. and Westwell, A. D. 2013. Convenient synthesis of substituted 2-phenylbenzothiazoles using solid-supported triphenylphosphine. Synthetic Communications 43 (19), pp.2656-2662. (10.1080/00397911.2012.730648)
- Westwell, A. D. , Hutchings, A. and Caldicott, D. G. E. 2013. The identification and chemical characterization of a new arylcyclohexylamine, methoxetamine, using a novel Emergency Department toxicosurveillance tool. Drug Testing and Analysis 5 (3), pp.203-207. (10.1002/dta.1375)
- Md Tohid, S. F. et al. 2012. Synthesis and evaluation of indole-containing 3,5-diarylisoxazoles as potential pro-apoptotic antitumour agents. European Journal of Medicinal Chemistry 56 , pp.263-270. (10.1016/j.ejmech.2012.08.009)
- Soukupova, J. et al., 2012. Inhibitors of Bcl-3 as a novel therapeutic strategy for HER2+ breast cancer. European Journal of Cancer 48 (5), pp.S225-S225.
- Cottens, S. et al., 2011. Ask the experts: future of the pharmaceutical industry. Future Medicinal Chemistry 3 (15)(10.4155/fmc.11.145)
- Altug, C. et al., 2011. An efficient one-pot multicomponent approach to 5-amino-7-aryl-8-nitrothiazolo[3,2-a]pyridines. Tetrahedron 67 (49), pp.9522-9528. (10.1016/j.tet.2011.10.005)
- Weekes, A. A. , Bagley, M. C. and Westwell, A. D. 2011. An efficient synthetic route to biologically relevant 2-phenylbenzothiazoles substituted on the benzothiazole ring. Tetrahedron 67 (40), pp.7743-7747. (10.1016/j.tet.2011.08.004)
- Brahemi, G. et al. 2010. Exploring the structural requirements for inhibition of the ubiquitin E3 ligase breast cancer associated protein 2 (BCA2) as a treatment for breast cancer. Journal of Medicinal Chemistry 53 (7), pp.2757-2765. (10.1021/jm901757t)
- Chew, E. et al., 2010. Cinnamaldehydes inhibit thioredoxin reductase and induce Nrf2: potential candidates for cancer therapy and chemoprevention. Free Radical Biology & Medicine 48 (1), pp.98-111. (10.1016/j.freeradbiomed.2009.10.028)
- Brahemi, G. et al. 2010. Homology Modelling of Human E1 Ubiquitin Activating Enzyme. Letters in Drug Design & Discovery 7 (1), pp.57-62. (10.2174/157018010789869316)
- Bruyere, H. , Westwell, A. and Jones, A. T. 2010. Tuning the pH sensitivities of orthoester based compounds for drug delivery applications by simple chemical modification. Bioorganic & Medicinal Chemistry Letters 20 (7), pp.2200-2203. (10.1016/j.bmcl.2010.02.035)
- Daniels, S. et al. 2010. The role and future potential of fluorinated biomarkers in positron emission tomography. Expert Opinion on Drug Discovery 5 (3), pp.291-304. (10.1517/17460441003652967)
- Weekes, A. A. et al., 2010. Rapid and convenient thermal or microwave-assisted synthesis of substituted 2-Phenylbenzothiazoles. Synthetic Communications 40 (20), pp.3027-3032. (10.1080/00397910903353739)
- Ziedan, N. I. et al., 2010. Design, synthesis and pro-apoptotic antitumour properties of indole-based 3,5-disubstituted oxadiazoles. European Journal of Medicinal Chemistry 45 (10), pp.4523-4530. (10.1016/j.ejmech.2010.07.012)
- Gan, F. F. et al., 2009. Structure-activity analysis of 2 '-modified cinnamaldehyde analogues as potential anticancer agents. Biochemical and Biophysical Research Communications 387 (4), pp.741-747. (10.1016/j.bbrc.2009.07.104)
- Weekes, A. A. and Westwell, A. 2009. 2-Arylbenzothiazole as a Privileged Scaffold in Drug Discovery. Current Medicinal Chemistry 16 (19), pp.2430-2440.
- Aiello, S. et al. 2008. Synthesis and biological properties of benzothiazole, benzoxazole, and chromen-4-one analogues of the potent antitumor agent 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (PMX 610, NSC 721648). Journal of Medicinal Chemistry 51 (16), pp.5135-5139. (10.1021/jm800418z)
- Brahemi, G. et al. 2008. Design and synthesis of BCA2 inhibitors. EJC Supplements 6 (12), pp.44.
- Huber, K. et al., 2008. 2- [(1-methylpropyl)dithio] -1H-imidazole inhibits tubulin polymerization through cysteine oxidation. Molecular Cancer Therapeutics 7 (1), pp.143-151. (10.1158/1535-7163.mct-07-0486)
- Kadri, H. et al. 2008. The design, synthesis and antitumour evaluation of novel small molecule inhibitors of the Dishevelled PDZ domain [Poster Presentation/Abstract]. EJC Supplements 6 (12), pp.137. 436. (10.1016/S1359-6349(08)72370-X)
- Kadri, H. et al. 2008. Synthesis and antitumour evaluation of novel 2-phenylbenzimidazoles. Journal of Enzyme Inhibition and Medicinal Chemistry 23 (5), pp.641-647. (10.1080/14756360802205398)
- Westwell, A. 2008. Advances in Cancer Drug Discovery - A British Association for Cancer Research Meeting. IDrugs 11 (11), pp.783-786.
- White, A. W. , Westwell, A. and Brahemi, G. 2008. Protein-protein interactions as targets for small-molecule therapeutics in cancer. Expert Reviews in Molecular Medicine 10 (e8), pp.1-14. (10.1017/S1462399408000641)
- Ziedan, N. , Westwell, A. and Fogli, S. 2008. Design and synthesis of novel indole derivatives as selective apoptosis-inducers. EJC Supplements 6 (12), pp.45-46.
- Athanasiou, A. et al., 2007. Cannabinoid receptor agonists are mitochondrial inhibitors: A unified hypothesis of how cannabinoids modulate mitochondrial function and induce cell death. Biochemical and Biophysical Research Communications 364 (1), pp.131-137. (10.1016/j.bbrc.2007.09.107)
- Athanasiou, A. et al., 2007. Vanilloid receptor agonists and antagonists are mitochondrial inhibitors: how vanilloids cause non-vanilloid receptor mediated cell death. Biochemical and Biophysical Research Communications 354 (1), pp.50-55. (10.1016/j.bbrc.2006.12.179)
- Henriksen, G. et al., 2007. Metabolically stabilized benzothiazoles for imaging of amyloid plaques. Journal of Medicinal Chemistry 50 (6), pp.1087-1089. (10.1021/jm061466g)
- Matsuura, T. et al., 2007. Basal and angiotensin II-inhibited neuronal delayed-rectifier K+ current are regulated by thioredoxin. American Journal of Physiology -Cell Physiology 293 (1), pp.C211-C217. (10.1152/ajpcell.00615.2006)
- Westwell, A. D. et al. 2006. Antitumor benzothiazoles. 26. 2-(3,4-Dimethoxyphenyl)-5-fluorobenzothiazole (GW 610, NSC 721648), a simple fluorinated 2-arylbenzothiazole, shows potent and selective inhibitory activity against lung, colon, and breast cancer cell lines. Journal of Medicinal Chemistry 49 (1), pp.179-185. (10.1021/jm050942k)
- Westwell, A. D. et al. 2005. Quinols as novel therapeutic agents. 2. 4-(1-Arylsulfonylindol-2-yl)-4-hydroxycyclohexa-2,5-dien-1-ones and related agents as potent and selective antitumor agents. Journal of Medicinal Chemistry 48 (2), pp.639-644. (10.1021/jm040859h)
- Westwell, A. D. et al. 2003. 4-Substituted-4-hydroxycyclohexa-2,5-dien-1-ones with selective activities against colon and renal cancer cell lines. Journal of Medicinal Chemistry 46 (4), pp.532-541. (10.1021/jm020984y)
- Hutchinson, I. et al., 2001. Antitumor benzothiazoles. 14. Synthesis and in vitro biological properties of fluorinated 2-(4-aminophenyl)benzothiazoles. Journal of Medicinal Chemistry 44 (9), pp.1446-1455. (10.1021/jm001104n)
Llyfrau
- Westwell, A. D. ed. 2016. Fluorinated pharmaceuticals: advances in medicinal chemistry. Future Medicine. (10.4155/9781909453968)
Ymchwil
Diddordebau ymchwil
Ar ôl hyfforddi mewn cemeg organig synthetig, mae prif ffocws fy ngweithgareddau ymchwil yn ystod y blynyddoedd diwethaf wedi bod ym maes cemeg feddyginiaethol a darganfod cyffuriau canser.
Rwy'n gemegydd meddyginiaethol gyda phrofiad helaeth o ddylunio, synthesis a gwerthuso biolegol moleciwlau bach ar gyfer darganfod cyffuriau a diagnosteg. Gellir rhannu fy niddordebau ymchwil yn y categorïau canlynol:
- Darganfod cyffuriau wedi'u targedu mewn canser y colon a'r fron datblygedig / metastatig (ataliad Bcl-3)
- Targedu bôn-gelloedd canser ar gyfer ymsefydlu apoptosis dethol (ataliad c-Flip)
- Nodweddu sylweddau seicoweithredol newydd, o safbwynt lleihau niwed
Dylunio a darganfod cyffuriau canser
Yn flaenorol, rwyf wedi bod yn rhan o amrywiaeth o brosiectau darganfod cyffuriau canser, gan ddefnyddio dulliau sgrinio sy'n seiliedig ar gelloedd i nodi cyfansoddion newydd o ddiddordeb. Mae un o'r prosiectau darganfod hyn wedi arwain at adnabod asiant newydd a aeth ymlaen i dreial clinigol (Phortress). Mae gweithgareddau ymchwil diweddar eraill yn cynnwys:
- Diraddio protein wedi'i dargedu (PROTACs) fel dull therapiwtig mewn therapi canser
- Targedau rhyngweithio protein-protein mewn canser
- Ymsefydlu detholus o apoptosis mewn celloedd canser
- Delweddu diagnostig (radiocemeg 18F) mewn canser gan ddefnyddio Tomograffeg Allyriadau Positron (PET).
- Nodweddu sylweddau seicoweithredol newydd (Prosiect WEDINOS), a gynhaliwyd ar y cyd â Bwrdd Iechyd Prifysgol Iechyd Cyhoeddus Cymru a'r Fro (Ysbyty Llandochau).
Cydweithwyr
Prifysgol Caerdydd
- Yr Athro Richard Clarkson (Ysgol y Biowyddorau)
- Yr Athro Arwyn Jones (Ysgol Fferylliaeth a Gwyddorau Fferyllol)
Allanol
- Yr Athro Andrea Brancale (Prifysgol Cemeg a Thechnoleg, Prague)
- Dean Acreman, Rick Lines, Joanne Rogers, Mary Busby (prosiect WEDINOS, Iechyd Cyhoeddus Cymru a GIG Cymru)
- Yr Athro Karl Hoffmann (Prifysgol Aberystwyth, Cymru)
Arbenigedd Allweddol
- Cemeg feddyginiaethol a dylunio cyffuriau
- Nodweddu cyffuriau dadansoddol
Cyllid ymchwil cyfredol
- 2024-6 Ymchwil Canser Cymru: Datblygu PROTACs newydd (PDRA: Dr. Dusan Ruzic)
- 2025-8 Ymddiriedolaeth Myristica: Atalyddion BCL3 newydd (ysgoloriaeth PhD: Tia Elstow)
- 2012- Iechyd Cyhoeddus Cymru (Llywodraeth Cymru) / GIG Cymru: Prosiect Sylweddau Seicoweithredol Newydd – Gweithredu yng Nghymru. Cyfraniad: dadansoddi cyffuriau trwy sbectrosgopeg NMR.
Addysgu
- PH3115 Optimeiddio dylunio cyffuriau
- PH4116 Prosiect ymchwil neu ysgoloriaeth fferylliaeth (tîm rheoli modiwl)
- PH4117 Gwyddorau fferyllol, ymarfer fferylliaeth a'r boblogaeth (arweinydd modiwl)
Bywgraffiad
Proffil gyrfa
Graddiais gyda gradd mewn Cemeg o Brifysgol Leeds ym 1990, ac yna cwblheais PhD mewn cemeg organig synthetig o'r un adran o dan oruchwyliaeth yr Athro Chris Rayner. Yn dilyn swydd ôl-ddoethurol o ddwy flynedd yn yr Adran Cemeg ym Mhrifysgol Loughborough o dan oruchwyliaeth yr Athro Jonathan Williams ac yna'r Athro Chris Moody, cefais fy mhenodi'n Gymrawd Ymchwil yn y Labordai Ymchwil Canser ym Mhrifysgol Nottingham, gyda'r Athro Malcolm Stevens. Cefais fy mhenodi i Ddarlithiaeth a ariennir gan Ymchwil Canser y DU yn 2001 yn yr Ysgol Fferylliaeth yn Nottingham, a symudais i'r Ysgol Fferylliaeth a Gwyddor Fferyllol yn 2006 i ymgymryd â swydd fel Uwch Ddarlithydd mewn Cemeg Feddyginiaethol. Cefais fy dyrchafu'n Ddarllenydd yn 2013, ac yn Athro yn 2016.
Gwasanaeth gwyddonol a phroffesiynol
Rwy'n gwasanaethu fel aelod Bwrdd Annibynnol (Prifysgol) ar gyfer Ymddiriedolaeth GIG Prifysgol Felindre (ers mis Awst 2021).
Rwy'n cadeirio bwrdd rheoli Medicentre Caerdydd (https://www.cardiff.ac.uk/medicentre), menter ar y cyd rhwng Prifysgol Caerdydd a Bwrdd Iechyd Prifysgol Caerdydd a'r Fro.
Rwy'n gyn-drysorydd ar gyfer Cymdeithas Ymchwil Canser Prydain, sefydliad elusennol o dros 1000 o weithwyr proffesiynol canser, ac wedi bod yn rhan o drefnu nifer o gynadleddau sy'n gysylltiedig ag ymchwil canser.
Rwy'n Athro Anrhydeddus ym Mhrifysgol Amity (Uttar Pradesh, India), o fewn Sefydliad Meddygaeth Moleciwlaidd ac Ymchwil Bôn-gelloedd Amity
Gwobrau / aelodaeth o gyrff proffesiynol
-
Enillydd gwobr goffa Malcolm Campbell y Gymdeithas Gemeg Frenhinol yn 2003 (gydag MFG Stevens a'r TD Bradshaw).
- Aelod o Gymdeithasau Ymchwil Canser Prydain ac Ewrop (BACR ac EACR).
- Rwy'n gwasanaethu fel aelod bwrdd gwyddonol ar gyfer grŵp PAMM (Ffarmacoleg a Mecanweithiau Moleciwlaidd), adran labordy o'r EORTC.
News articles
Contact Details
Themâu ymchwil
Arbenigeddau
- Cemeg meddyginiaethol a biomolecwlaidd
